| Trial ID: | L4192 |
| Source ID: | NCT02150824
|
| Associated Drug: |
Placebo
|
| Title: |
Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Placebo|DRUG: Placebo|DRUG: Placebo|DRUG: BI 187004|DRUG: Placebo|DRUG: BI 187004|DRUG: BI 187004|DRUG: BI 187004
|
| Outcome Measures: |
Primary: The percentage of patients with drug- related adverse events, 6 weeks | Secondary: Change from baseline in fasting plasma glucose (FPG) after 28 days of treatment, 4 weeks
|
| Sponsor/Collaborators: |
Sponsor: Boehringer Ingelheim
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
103
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2014-07
|
| Completion Date: |
2015-08
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-14
|
| Locations: |
1307.4.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany|1307.4.49002 Boehringer Ingelheim Investigational Site, Mainz, Germany|1307.4.49001 Boehringer Ingelheim Investigational Site, Neuss, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT02150824
|
